Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2016-04-05

FDA Approved: INFLECTRA — Original Application (Pfizer Laboratories Div Pfizer Inc)

View source ↗

Summary

FDA approved INFLECTRA (infliximab-dyyb) as a biosimilar to infliximab for multiple autoimmune diseases, expanding access to a biologic therapy with indications…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • INFLECTRA (infliximab-dyyb)

Snippet

ORIG AP for INFLECTRA (INFLIXIMAB-DYYB)